Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026

ALNY vs REGN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

REGN Wins Head-to-Head Institutional Verdict (3–3 across 6 Pillars · 6–4 Matrix Metrics)

REGN Overall Winner 6-Pillar Tally: ALNY 3 – 3 REGN Matrix Metrics: ALNY 4 – 6 REGN

As of Nov 19, 2026, Regeneron Pharmaceuticals Inc (REGN) is the stronger overall head-to-head candidate over Alnylam Pharmaceuticals, Inc. (ALNY) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Growth & Scale, Balance Sheet & Cash Flow, Options & Positioning). ALNY carries a Unified Composite Score of 50.9/100 (HOLD) at $147.82 (15.0x Forward P/E, 19.5% operating margin), whereas REGN carries 42.6/100 (HOLD) at $923.34 (14.9x Forward P/E, 30.4% operating margin).

  • Composite vs. Pillar Nuance: While ALNY currently prints a higher short-term Unified Composite Score (50.9/100 HOLD vs. REGN 42.6/100 HOLD), REGN captures the overall institutional head-to-head verdict (6–4 matrix metrics and 3–3 across the 6 pillars) due to superior fundamental profitability (30.4% vs. 19.5% operating margin) and revenue trajectory (+36.3% vs. +16.7% YoY).
  • Technical & Structure Timing Caution: ALNY is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 28.0); meanwhile REGN trades in a Markup technical trend (CONSOLIDATION options phase, RSI 57.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ALNY vs REGN
ALNY NASDAQ
Alnylam Pharmaceuticals, Inc.
Pharmaceutical Preparations
$147.82
-1.06% 1D
Market Cap $20.0B
TTM Revenue $5.01B
Forward P/E 15.0x
Beta / 30D Vol 0.55β · 94% Vol
Unified Composite Score
50.9 / 100 HOLD
Tech 45.0 Fund 64.0 Flow 67.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -11.8%), weak momentum, RSI 28
RSI-14: 28.0 · SMA20: $172.23 · SMA50: $210.88
REGN NASDAQ Head-to-Head Winner
Regeneron Pharmaceuticals Inc
Pharmaceutical Preparations
$923.34
-2.35% 1D
Market Cap $97.8B
TTM Revenue $16.9B
Forward P/E 14.9x
Beta / 30D Vol 0.32β · 55% Vol
Unified Composite Score
42.6 / 100 HOLD
Tech 19.0 Fund 45.0 Flow 68.0 Mom 56.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (4.5% over 20 days), RSI 58
RSI-14: 57.9 · SMA20: $907.12 · SMA50: $826.97

6-Pillar Scorecard Institutional Category Breakdown (ALNY 3 – 3 REGN)

Columns: Metric · ALNY · REGN
1. Valuation Multiples ALNY
Forward P/E 15.0x 14.9x
Trailing P/E 7.5x 20.9x
PEG Ratio 0.21x 1.15x
EV / Revenue 3.9x 5.7x
2. Growth & Scale REGN
Revenue Growth (YoY) +16.7% +36.3%
Earnings Growth (YoY) +633.5% +35.5%
TTM Revenue (USD) $5.01B $16.9B
Market Cap $20.0B $97.8B
3. Profitability & Quality ALNY
Gross Margin 77.3% 46.7%
Operating Margin 19.5% 30.4%
Net Profit Margin 52.8% 28.5%
Return on Equity (ROE) 138.1% 14.9%
4. Balance Sheet & Cash Flow REGN
Cash Generation (TTM) $752M $3.63B
Cash Flow Margin 15.0% 21.5%
Net Cash / Leverage $492M Net Cash $952M Net Cash
Dividend Yield None (0.00%) 0.39%
5. Options & Positioning REGN
Options Structure Phase BREAKDOWN CONSOLIDATION
Current IV / %ile 49.9% (34th %ile) 35.5% (6th %ile)
Put/Call OI Skew 0.85x (Call-Skewed) 0.47x (Call-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Markdown ACCUMULATION · Markup
6. R&D & Supply-Chain Moat ALNY
OpEx & R&D Intensity 57.8% of Rev ($2.90B) 16.3% of Rev ($2.75B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat High-Margin Pricing Power Moat High-Margin Pricing Power Moat
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ALNY (4) vs REGN (6)
Institutional Metric ALNY REGN Criterion Row Edge
Market Capitalization
Scale
$20.0B $97.8B Larger Scale REGN
Trailing P/E Ratio
Valuation
7.5x 20.9x Lower Multiple ALNY
Forward P/E Ratio
Valuation
15.0x 14.9x Lower Multiple REGN
Revenue Growth (YoY)
Growth
+16.7% +36.3% Higher Growth REGN
Operating Margin (TTM)
Profitability
19.5% 30.4% Higher Margin REGN
Net Profit Margin
Profitability
52.8% 28.5% Higher Margin ALNY
Return on Equity (ROE)
Capital Efficiency
138.1% 14.9% Higher ROE ALNY
52-Week Range Position
Momentum
0% ($147–$477) 83% ($592–$992) Stronger Trend REGN
Beta / 30D Volatility
Risk Regime
0.55β · 94% Vol 0.32β · 55% Vol Lower Realized Risk REGN
Unified Institutional Score
Composite Signal
50.9 / 100 (HOLD) 42.6 / 100 (HOLD) Higher Composite ALNY
Trailing 12M Revenue (USD)
Operating Scale
$5.01B $16.9B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
77.3% 46.7% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
0.21x PEG · 3.9x EV/Rev 1.15x PEG · 5.7x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$752M ($492M Net Cash) $3.63B ($952M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon REGN +48.94 pp
ALNY: -34.33% · REGN: +14.61%
3M Horizon REGN +48.13 pp
ALNY: -37.42% · REGN: +10.71%
6M Horizon REGN +94.5 pp
ALNY: -50.81% · REGN: +43.69%
1Y Horizon REGN +95.33 pp
ALNY: -68.03% · REGN: +27.3%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period ALNY Revenue REGN Revenue ALNY Op. Margin REGN Op. Margin Margin Leader
FY2018 $70M $5.15B -1087.6% 49.3% REGN
FY2019 $220M $6.56B -427.5% 33.7% REGN
FY2020 $490M $8.50B -168.1% 42.1% REGN
FY2021 $840M $16.1B -83.9% 55.7% REGN
FY2022 $1.04B $12.2B -75.7% 38.9% REGN
FY2023 $1.83B $13.1B -15.4% 30.9% REGN
FY2024 $2.25B $14.2B -7.9% 28.1% REGN
FY2025 $3.71B $14.3B 13.5% 24.9% REGN

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ALNY BREAKDOWN
55d in phase · OBV DISTRIBUTION
Current IV 49.9%
IV Percentile 34th %ile
Put/Call OI Skew 0.85x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact ALNY Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
REGN CONSOLIDATION
55d in phase · OBV ACCUMULATION
Current IV 35.5%
IV Percentile 6th %ile
Put/Call OI Skew 0.47x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact REGN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $159.73 · IV 50.9%

ALNY vs. REGN: Simulated 5-Day Option Payoffs & Capital Efficiency

Compare 100 shares of ALNY ($15,973) vs. REGN ($95,240) against risk-defined 5-day vertical and put-wall option structures.

ALNY Spot $159.73 · IV 50.9%
ALNY Options Simulator →
5-DAY BULLISH SWING Liq B

Dec 18 $165 / $180 Bull Call Spread

Buy 1x $165C · Sell 1x $180C · 32d

Net Entry $395 Debit
T+5d @ +5% Move +$161 (+41%)
Max Risk / Buffer $395 Capped
5d Edge & Liquidity 0.9x R:R · Liq B
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME Liq B

Dec 18 $145 / $135 Bull Put Spread

Sell 1x $145P · Buy 1x $135P · 32d

Net Entry $165 Credit
Max Credit / Yield +$165 (+19.8% RoM)
Max Risk / Buffer -10.3% Cushion ($835 Mgn)
5d Edge & Liquidity 79% PoP · Liq B
Simulate 5-Day Payoff →
REGN Spot $952.40 · IV 33.5%
REGN Options Simulator →
5-DAY BULLISH SWING Liq C

Dec 18 $950 / $1,000 Bull Call Spread

Buy 1x $950C · Sell 1x $1,000C · 31d

Net Entry $2,387 Debit
T+5d @ +5% Move +$891 (+37%)
Max Risk / Buffer $2,387 Capped
5d Edge & Liquidity 0.8x R:R · Liq C
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME Liq C

Jan 15 '27 $880 / $820 Bull Put Spread

Sell 1x $880P · Buy 1x $820P · 59d

Net Entry $1,367 Credit
Max Credit / Yield +$1,367 (+29.5% RoM)
Max Risk / Buffer -9.0% Cushion ($4,633 Mgn)
5d Edge & Liquidity 75% PoP · Liq C
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ALNY Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $20.0B market capitalization and 19.5% operating margin.
OpEx & R&D Reinvestment 57.8% of Rev ($2.90B)
90D Engineering Disclosures 0 Published
REGN Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $97.8B market capitalization and 30.4% operating margin.
OpEx & R&D Reinvestment 16.3% of Rev ($2.75B)
90D Engineering Disclosures 0 Published

Investor FAQ ALNY vs REGN Key Questions & Quantitative Answers

As of Nov 19, 2026, Regeneron Pharmaceuticals Inc (REGN) is the stronger overall head-to-head candidate over Alnylam Pharmaceuticals, Inc. (ALNY) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Growth & Scale, Balance Sheet & Cash Flow, Options & Positioning). ALNY carries a Unified Composite Score of 50.9/100 (HOLD) at $147.82 (15.0x Forward P/E, 19.5% operating margin), whereas REGN carries 42.6/100 (HOLD) at $923.34 (14.9x Forward P/E, 30.4% operating margin). Composite vs. Pillar Nuance: While ALNY currently prints a higher short-term Unified Composite Score (50.9/100 HOLD vs. REGN 42.6/100 HOLD), REGN captures the overall institutional head-to-head verdict (6–4 matrix metrics and 3–3 across the 6 pillars) due to superior fundamental profitability (30.4% vs. 19.5% operating margin) and revenue trajectory (+36.3% vs. +16.7% YoY). Technical & Structure Timing Caution: ALNY is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 28.0); meanwhile REGN trades in a Markup technical trend (CONSOLIDATION options phase, RSI 57.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

REGN leads the Growth & Scale pillar: ALNY posts +16.7% YoY revenue growth and +633.5% YoY earnings growth on $5.01B TTM revenue (77.3% gross margin, 19.5% operating margin), compared with REGN at +36.3% YoY revenue growth and +35.5% YoY earnings growth on $16.9B TTM revenue (46.7% gross margin, 30.4% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), ALNY cumulative revenue shifted +5200.0% while REGN shifted +178.4%. In operating R&D and SG&A reinvestment, ALNY deploys 57.8% of Rev ($2.90B) (0 90-day corporate R&D disclosures) versus 16.3% of Rev ($2.75B) (0 disclosures) for REGN.

ALNY screens cheaper on headline valuation multiples. ALNY trades at 15.0x Forward P/E, 7.5x Trailing P/E, 0.21x PEG, and 3.9x EV/Revenue (15.0% FCF margin), whereas REGN trades at 14.9x Forward P/E, 20.9x Trailing P/E, 1.15x PEG, and 5.7x EV/Revenue (21.5% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ALNY (138.1% ROE) versus REGN (14.9% ROE) capital efficiency.

In options market volatility and institutional positioning, ALNY carries 49.9% implied volatility (34th %ile, Balanced (25th–60th %ile)), a 0.85x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.55β · 94% Vol realized risk). By comparison, REGN carries 35.5% implied volatility (6th %ile, Compressed (<25th %ile)), a 0.47x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.32β · 55% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.